Your session is about to expire
← Back to Search
EPR Oximetry for Peripheral Neuropathy (CIPN Trial)
N/A
Waitlist Available
Led By Victoria H Lawson, M.D.
Research Sponsored by Dartmouth-Hitchcock Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Scheduled to receive chemotherapy with taxane compounds for the treatment of breast cancer.
No prior taxane or platinum chemotherapy prior to enrollment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
CIPN Trial Summary
This trial will study whether markers of tissue oxygen and a protein called neurofilament light chain could be used to predict chemotherapy-induced peripheral neuropathy.
Eligible Conditions
- Chemotherapy-induced Peripheral Neuropathy
CIPN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCIPN Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Tissue Oxygenation
Secondary outcome measures
Nerve Conduction Studies
Neurologic Examination
Serum NF-L levels
CIPN Trial Design
1Treatment groups
Experimental Treatment
Group I: EPR OximetryExperimental Treatment1 Intervention
All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EPR Oximetry
2018
N/A
~10
Find a Location
Who is running the clinical trial?
Dartmouth-Hitchcock Medical CenterLead Sponsor
521 Previous Clinical Trials
2,542,392 Total Patients Enrolled
1 Trials studying Peripheral Neuropathy
10 Patients Enrolled for Peripheral Neuropathy
Disarm TherapeuticsIndustry Sponsor
1 Previous Clinical Trials
200 Total Patients Enrolled
Victoria H Lawson, M.D.Principal InvestigatorDartmouth-Hitchcock Medical Center
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there still capacity to take part in this research?
"According to the clinicaltrials.gov website, this particular medical trial is not currently enrolling patients. This study was initially announced on March 1st 2018 and last updated February 17th 2022. Despite that, there are 184 additional trials actively searching for volunteers right now."
Answered by AI
Share this study with friends
Copy Link
Messenger